Fluzone QIV HD is under clinical development by Sanofi and currently in Phase II for Unspecified Influenza Virus Infections.

SP-0230 is under clinical development by Sanofi and currently in Phase II for Neisseria meningitidis Infections.

In connection with the start of the phase 3 trials of PCV21, Sanofi has expanded its alliance with South Korea-based SK Bio, ...

The increases are to list prices, which do not include rebates to pharmacy benefit managers and other discounts.

Still, many analysts on Wall Street think the correction is way overdone. Regeneron's stock could soar by 50% in the next ...

Cytokinetics finds a new partner in Greater China for its potential blockbuster drug — it could be one of a handful of ...

Sanofi's SNY short percent of float has fallen 15.0% since its last report. The company recently reported that it has 3.74 ...

Sanofi is handing SK bioscience 50 million euros ($52 million) as the longtime partners take their next-gen pneumococcal ...

Sanofi and SK bioscience have entered into a new chapter of their collaboration in pneumococcal vaccines with an expanded agreement to develop, license and commercialize next-generation PCVs for both ...

French pharma major Sanofi says it has entered into a new chapter of the collaboration with South Korean firm SK bioscience ...

Today's Research Daily features new research reports on 16 major stocks, including ServiceNow, Inc. (NOW), Advanced Micro ...

Sanofi (SNYNF, SNY) and SK bioscience have entered an expanded agreement to develop, license and commercialize next-generation ...